AVALO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
AVALO THERAPEUTICS, INC. (AVTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 46.25 thousand shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2018-04-02
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-12-31 was 27.86K shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-09-30 was 0.00 shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-06-30 was 6.25K shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2017-03-31 was 12.14K shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 46.25K shares, a 84.46% increase from fiscal 2016.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 25.07K shares, a 78.56% decline from fiscal 2015.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2015 was 116.93K shares, a 1719.32% increase from fiscal 2014.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2014 was 6.43K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2017-12-31 | 27.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | 27.86K shares derived: sum of 2 quarters · filed 2018-04-02 | 34.10K shares derived: sum of 3 quarters · filed 2018-04-02 | 46.25K shares 10-K · filed 2018-04-02 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 6.25K shares derived: sum of 2 quarters · filed 2017-11-07 | 18.39K shares 10-Q · filed 2017-11-07 | |
| 2017-06-30 | 6.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 18.39K shares 10-Q · filed 2017-08-14 | ||
| 2017-03-31 | 12.14K shares 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | 25.07K shares 10-K · filed 2018-04-02 | |||
| 2015-12-31 | 2.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 116.93K shares 10-K · filed 2017-03-14 | ||
| 2015-09-30 | 114.70K shares 10-Q · filed 2015-11-13 | |||
| 2014-12-31 | 6.43K shares 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |